Pharmaceuticals
turnover in the nine months was £12,690 million, down 2% AER,
1% CER, but grew 11% AER, 12% CER excluding the impact of the
decline in Established Pharmaceuticals turnover. HIV sales were
flat at AER and up 1% CER, to £3,608 million, with growth in
Juluca and Dovato partly offset by declines in
Tivicay and Triumeq. Respiratory sales were up 25%
AER, 26% CER, to £2,732 million, on growth of Trelegy, Nucala and Relvar/Breo. Sales of Established
Pharmaceuticals declined 16% AER, 14% CER to £5,572
million.
Towards
the end of the first quarter, additional demand related to the
COVID-19 pandemic had a positive impact on growth of HIV and
Respiratory products. This effect broadly reversed in the second
quarter, which also saw lower levels of new patient prescriptions
in US and Europe and reduced market demand for allergy and
antibiotic products in International and Europe. These effects
continue to be seen in the third quarter.
In the
US, sales grew 1% AER, 1% CER. Continued growth of Nucala, Trelegy, Benlysta, Zejula and the HIV two-drug
regimens was partly offset by the decline in Tivicay, Triumeq and Established Products,
including the impact of generic albuterol substitutes.
In
Europe, sales declined 1% AER, 1% CER, with growth from
Respiratory, HIV and Oncology partly offset by the decline of
Established Pharmaceutical sales, impacted by generic competition
and lower demand for antibiotics during the COVID-19 pandemic
period. Approximately two percentage points of decline are due to
the impact of a one-off UK Relenza contract in the
comparator.
International
declined 7% AER, 3% CER, with Respiratory, HIV and Benlysta growth partly offset by lower
Established Pharmaceutical sales. This included the impact of a
weaker allergy season and generic competition for Avolve in Japan and government mandated
changes increasing the use of generics in China.
Respiratory
Total
Respiratory sales were up 25% AER, 26% CER, with strong growth in
all regions. International Respiratory sales grew 26% AER, 29% CER
including Nucala, up 43%
AER 43% CER and Relvar/Breo, up 11% AER, 14% CER to
£245 million. In Europe, Respiratory sales grew to £691
million up 21% AER, 22% CER. In the US, Trelegy and Nucala growth continued while
Relvar/Breo sales grew 34%
AER, 35% CER, including the effect of a prior period RAR adjustment
and a stronger US ICS/LABA market in the COVID-19 pandemic
environment.
Sales
of Nucala were £702
million in the nine months and grew 28% AER, 28% CER, with US sales
up 29% AER, 30% CER to £414 million. Europe sales of £175
million grew 17% AER 17% CER and International sales of £113
million grew 43% AER, 43% CER.
Trelegy sales were up 68% AER, 69% CER to £581 million
driven by growth in all regions. In the US, the new asthma
indication was approved and launched in Q3 2020, with sales up 56%
AER, 57% CER to £400 million. In Europe, sales grew 74% AER,
75% CER and in International, sales grew to £61 million in the
nine months.
Relvar/Breo sales were up 21% AER, 22% CER to £850
million in the nine months. In the US, Relvar/Breo grew 34% AER, 35% CER,
benefiting from the effect of a prior period RAR adjustment and a
stronger US ICS/LABA market in the COVID-19 pandemic environment.
In Europe and International, Relvar/Breo continued to grow, up 14%
AER, 14% CER and 11% AER, 14% CER respectively.
HIV
HIV
sales were £3,608 million, flat at AER, up 1% CER in the nine
months. The dolutegravir franchise grew 2% AER, 3% CER, delivering
sales of £3,477 million. The remaining portfolio, with sales
of £131 million and 4% of total HIV sales, declined 24% AER,
24% CER and reduced the overall growth of total HIV by two
percentage points at CER.
Sales
of dolutegravir products were £3,477 million in the nine
months. Tivicay delivered
sales of £1,162 million, down 6% AER, 5% CER and Triumeq sales were £1,726 million,
down 10% AER, 9% CER. The two-drug regimens, Juluca and Dovato delivered sales of £589
million in the nine months, with combined growth more than
offsetting decline in the three-drug regimen, Triumeq.
In the
US, dolutegravir sales declined 1% AER, but were flat at CER, and
in Europe dolutegravir sales grew 5% AER, 5% CER. Following recent
launches of Dovato,
combined sales of the two-drug regimens were £429 million in
the US and £143 million in Europe, with growth offsetting the
decline in Triumeq.
International continued to grow strongly with total dolutegravir
sales growth of 6% AER, 11% CER, driven by Tivicay tender business.
Oncology
Sales
of Zejula, the PARP
inhibitor asset acquired from Tesaro in Q1 2019 were £250
million in the nine months, up 53% AER, 53% CER.
Blenrep for the treatment of patients with relapsed or
refractory multiple myeloma was approved and launched in the US and
Europe in Q3 2020 and reported sales of £8
million.
Immuno-inflammation
Sales
of Benlysta in the nine
months were up 16% AER, 17% CER to £514 million, including
sales of the sub-cutaneous formulation of £249 million up 32%
AER, 32% CER.
Duvroq for patients with anaemia due to chronic kidney
disease was launched in Japan in Q3 2020 and reported sales in the
International region of £7 million.
Established Pharmaceuticals
Sales
of Established Pharmaceuticals in the nine months were £5,572
million, down 16% AER, 14% CER.
Established
Respiratory products declined 15% AER, 13% CER to £2,495
million. Advair/Seretide
and Ventolin were impacted
by generic substitutes in the US and Europe, and Flovent experienced price pressure in
the US. In the International region, allergy sales were impacted by
market contraction in Japan.
The
remainder of the Established Pharmaceuticals portfolio declined 16%
AER, 14% CER to £3,077 million on lower demand for antibiotics
during the COVID-19 pandemic period, the impact of government
mandated changes increasing use of generics in markets including
France and China, and a strong comparator, including a European
Relenza
contract.
|